Cargando…
Myeloma Therapy Pursuing the Plasma Cell /
Therapeutic options for patients with myeloma have radically changed over the past ten years. Myeloma Therapy: Pursuing the Plasma Cell provides updated various treatment options for patients with myeloma, with focus on the emerging and speculative aspects of myeloma therapy. Written by clearly ackn...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Totowa, NJ :
Humana Press : Imprint: Humana,
2008.
|
| Edición: | 1st ed. 2008. |
| Colección: | Contemporary Hematology
|
| Temas: | |
| Acceso en línea: | Texto Completo |
Tabla de Contenidos:
- Biologic Consideration and Myeloma
- Staging in Multiple Myeloma
- Epidemiology of Multiple Myeloma
- Basic Biology of Plasma Cell Dyscrasias: Focus on the Role of the Tumor Microenviroment
- Biology-Based Classification and Staging of Multiple Myeloma
- Cytogenetic Abnormalities in Multiple Myeloma: The Importance of FISH and Cytogenetics
- Historical and Cytotoxic Agent-Based Therapies for Myeloma
- Role of Autologous Stem Cell Transplantation in Multiple Myeloma
- Maintenance Therapy in Multiple Myeloma
- Therapy for Patients not Eligible for Autologous Transplant
- Current Role of Anthracyclines in the Treatment of Multiple Myeloma
- Immune-Based Therapies
- Allogeneic Transplantation for Multiple Myeloma
- Immunobiology and Immunotherapy of Multiple Myeloma
- Antibody and Other Immune-Based Therapies for Myeloma
- Existing Novel Agents
- Thalidomide in Patients with Relapsed Multiple Myeloma
- Thalidomide: Induction Therapy
- The Role of Bortezomib in the Treatment of Relapsed and Refractory Multiple Myeloma
- Bortezomib as Induction Therapy in Patients with Multiple Myeloma
- Lenalidomide in Relapsed or Refractory Multiple Myeloma
- Lenalidomide for Initial Therapy of Newly Diagnosed Multiple Myeloma
- Current and Future Targets
- The Role of Heat Shock Protein 90 as a Therapeutic Target for Multiple Myeloma
- The PI3 Kinase/Akt Pathway as a Therapeutic Target in Multiple Myeloma
- The Mammalian Target of Rapamycin and Multiple Myeloma
- CDK Inhibitors in Multiple Myeloma
- Fibroblast Growth Factor Receptor 3 and Multiple Myeloma
- Histone Deacetylase Inhibitors in Multiple Myeloma
- Death Receptors in Multiple Myeloma and Therapeutic Opportunities
- Proteasome Inhibitors as Therapy in Multiple Myeloma
- Supportive Care
- Pathophysiology of Bone Disease in Multiple Myeloma
- Anemia and Erythropoeitic Growth Factors in Multiple Myeloma
- Percutaneous Vertebroplasty and Balloon Kyphoplasty for the Treatment of Acute Painful Pathologic and Nonpathologic Fractures
- The Role of Anatomic and Functional Imaging in Myeloma
- Management of Multiple Myeloma Patients with Renal Dysfunction
- Other Plasma Cell Disorders
- Waldenstrom's Macroglobulinemia
- AL (Immunoglobulin Light-Chain) Amyloidosis
- POEMS Syndrome and Other Atypical Plasma Cell Disorders
- Monoclonal Gammopathy of Undetermined Significance.